SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is trending following the successful $900 million funding round for its robotics unit, valued at over $6 billion, sparking intense debate about whether the company should be valued as a physical AI leader rather than just an EV manufacturer. Investors are closely monitoring these robotics developments and upcoming earnings alongside broader market concerns about the volatility of Chinese ADRs.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh reported hardware price hikes and new AI infrastructure investments against skepticism from critics about the sustainability of current AI spending. Market attention is heavily focused on the upcoming earnings report, with community sentiment remaining split between bulls anticipating a blowout beat and bears bracing for a potential post-earnings pullback.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as CEO David Ellison initiates high-stakes negotiations with California Attorney General Rob Bonta to resolve a multistate antitrust lawsuit blocking the Warner Bros. Discovery merger. Investors are closely monitoring the potential for a settlement, especially as reports emerge of Paramount considering relocating its headquarters out of California if the litigation persists.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors monitor the anticipated 80th clinical event from the REGAL Phase 3 trial, with heavy community debate regarding buyout potential and the credibility of recent reports. While bullish participants see a pathway to a curative AML treatment, others remain skeptical about the trial's official status and market potential.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

PDD is trending as investors weigh strong e-commerce demand and growth against regulatory concerns, supply chain investment costs, and recent institutional portfolio adjustments. The community remains divided, with many focusing on the stock's low valuation and strong cash position while others express frustration over its lack of share buybacks and ongoing volatility.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently a focal point for investors, driven by community discussions comparing its valuation to technology stocks and high-profile investor sentiment that labels the company a reliable defensive holding. Traders are actively monitoring technical levels and potential membership-driven growth catalysts, maintaining a cautious yet observant stance as they track its performance relative to broader market volatility.

Ethena

The Ethena (ENA) community is actively debating its valuation metrics and structural leverage, with discussions focused on its high token density per share and perceived disconnect from its net asset value. Investors are closely monitoring the impact of institutional partnerships and potential regulatory developments on the token's long-term utility.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

Investors are rallying around RETIRE as a community-driven movement and a "tokenized 401(k)" alternative to traditional retirement funds. Supporters are actively participating in recurring dollar-cost averaging every Friday to build long-term conviction in the project's potential for financial freedom.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is gaining attention as investors weigh a major $1 billion contract award against broader concerns regarding the company's merger with Valaris and heavy debt. While community members are optimistic about the strengthening offshore drilling cycle and improved revenue visibility, some remain wary of potential share dilution and persistent institutional short interest.

TOSHI

TOSHI is trending as the community rallies around hopes for a potential short squeeze and future exchange listings, keeping sentiment bullish despite recent price volatility. Investors remain focused on building their positions while awaiting a catalyst to drive the asset toward higher valuation levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCryst Pharmaceuticals is trading lower ahead of upcoming earnings, with investors expressing significant frustration over persistent share price manipulation and stagnant performance despite recent positive fundamental developments. While the community is debating whether the current weakness is a shakeout ahead of a potential buyout or a result of underlying growth concerns, many remain focused on the company's rare disease franchise as a key long-term catalyst.

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors need to pay close attention to BCRX stock based on the movements in the options market lately. 

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation

Equity

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biocryst Pharmaceuticals Inc Q2 Profit Climbs

(RTTNews) - Biocryst Pharmaceuticals Inc (BCRX) released earnings for its second quarter that Increased, from the same period last year...

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect...

Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks. 

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.55
Prev Close	$9.66
Open	$9.72
Dividend Yield	0.00%
50-Day Moving Average	$9.60
Beta	0.94
Avg. Volume	3.88M
PE Ratio	-6.35

52-Week High	$11.22
52-Week Low	$6.00
Market Capitalization	$2.44B
EPS (Annual)	$1.21
Price to Book	-5.37
Revenue Per Employee	$2.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info